title: The frequency of pretransplant donor cytotoxic T cell precursors with anti-host specificity predicts survival of patients transplanted with bone marrow from donors other than HLA-identical siblings.
abstract: Transplantation with bone marrow from other than genotypically HLA-identical donors is associated with an increased incidence and severity of graft-versus-host disease (GvHD). The precise influence of HLA incompatibilities is not easy to analyze as even perfectly matched, HLA-identical unrelated donors might still express HLA differences that remain undetected by conventional typing. To measure T cell activity against serologically detectable and nondetectable HLA antigens, we analyzed the frequencies of CTL precursors (CTLp) between 11 unrelated HLA-matched and five related haploidentical donor/recipient pairs in graft-versus-host direction. Our results show that whenever HLA class I disparities could be identified by serology, high precursor frequencies (1/28,000-1/94,000) were measured. In contrast, in donor/recipient pairs that differed for class II only, no precursors were detected. CTLp were elevated in two out of eight fully matched donor/recipient combinations. These combinations displayed activities as high (1/21,000; 1/52,000) as the combinations that were serologically HLA class I disparate. The incompatibilities detected by the cellular assay were highly significant for the clinical results after transplantation. High CTLp frequencies before transplantation correlated with unfavorable clinical results independent of the incidence of detected HLA differences. Five out of the six patients with high (> 1/100,000) CTLp frequencies died within 120 days after transplantation. GvHD IV was the cause of death for all (3/5) patients who had received an unmanipulated bone marrow. In the group with intermediate or undetectable CTLp frequencies, eight out of 10 patients are alive, seven (CTLp frequency undetectable) without GvHD more severe than grade II, while one patient (CTLp frequency = 1/180,000) suffered from GvHD grade III. One patient rejected the graft and was rescued by an autologous BMT.
authors.affiliation: Department de Médecine, Hôpital Cantonal de Genève, Switzerland.
authors.forename: E
authors.initials: E
authors.lastname: Roosnek
authors.forename: S
authors.initials: S
authors.lastname: Hogendijk
authors.forename: S
authors.initials: S
authors.lastname: Zawadynski
authors.forename: D
authors.initials: D
authors.lastname: Speiser
authors.forename: J M
authors.initials: JM
authors.lastname: Tiercy
authors.forename: C
authors.initials: C
authors.lastname: Helg
authors.forename: B
authors.initials: B
authors.lastname: Chapuis
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: J
authors.initials: J
authors.lastname: Gmür
authors.forename: R
authors.initials: R
authors.lastname: Seger
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000401:mortality; D002648:Child; D005192:Family Health; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control*; D006680:HLA Antigens / Q000032:analysis*; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D013234:Stem Cells; D016019:Survival Analysis; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology*; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens